- Home
- TTNP
as 01-17-2025 3:44pm EST
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 3.0M | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 41.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $14.80 | Next Earning Date: | 01-03-2025 |
| Revenue: | N/A | Revenue Growth: | -66.97% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Titan Pharmaceuticals Inc. News
TTNP Breaking Stock News: Dive into TTNP Ticker-Specific Updates for Smart Investing
Associated Press Finance
15 days ago
Titan Pharmaceuticals: Q3 Earnings Snapshot
GlobeNewswire
2 months ago
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq
MT Newswires
5 months ago
Top Midday Gainers
MT Newswires
5 months ago
Sector Update: Health Care Stocks Rise Premarket Tuesday
MT Newswires
5 months ago
Top Premarket Gainers
MT Newswires
5 months ago
Titan Pharmaceuticals Signs Merger Agreement With KE Sdn. Bhd.
GlobeNewswire
5 months ago
Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.
Associated Press Finance
5 months ago
Titan Pharmaceuticals: Q2 Earnings Snapshot
Compare TTNP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TTNP Titan Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.